Jerusalem Startup eggXYt Launches Bid to Disrupt The Egg Industry
eggXYt, a Jerusalem-based genetic tech startup, is developing technology to save billions of baby chickens from unnecessary death, while generating significant savings for farmers. eggXYt
SpliSense Raises $28.5 Million for Treatment of CF
Jerusalem-based biopharmaceutical company SpliSense, which is developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, announced on Thursday the closing of
Smoking Cessation Becomes BrainsWay’s 3rd Noninvasive Brain Disorder Treatment
BrainsWay Ltd., a global leader in advanced noninvasive treatment of brain disorders, has started the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep
Purple Biotech Initiates Phase 1b/2 Clinical Trial of CM24 Therapy for Non-Small Cell Lung Cancer & Pancreatic Cancer
Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today
Oramed JV, Oravax Medical, & India’s Premas Biotech to Develop Oral COVID-19 Vaccines
Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech , a biotechnology firm based in Gurugram, India, to develop novel oral
Pepticom’s New Spinout Company, PeptiCov, to Focus on COVID-19
Pepticom, a leader in artificial intelligence peptide drug design and discovery, announced today that it has raised $2.6 million to establish a company to focus
BrainsWay Ltd. Closes $45.2 Million Underwritten Public Offering of American Depositary Share
BrainsWay Ltd. (NASDAQ & TASE: BWAY) a global leader in the advanced noninvasive treatment of brain disorders, closed its previously announced underwritten public offering of
Sanseera’s Blood Test Could Replace Cancer Biopsies
Hebrew University of Jerusalem researchers Dr. Ronen Sadeh and Prof. Nir Friedman have develop a simple blood test (liquid biopsy) that they say could replace
Gamida Cell Raises $75 Million Financing with Highbridge Capital Management
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to developing and commercializing cures for blood cancers and serious hematologic diseases, today announced
